GlassScriptPhysician profile
Mauri Lunderman
NPI 1033103825
$6,967.80
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,185 · 2020: $50.23 · 2021: $337 · 2022: $2,150 · 2023: $179 · 2024: $65.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $245.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,094.57 | 2019-2024 | Da Vinci Surgical System |
| Medical Device Business Services, INC. | $1,381.92 | 2019 | |
| Davol INC. | $458.09 | 2020-2022 | |
| Tela Bio, INC. | $457.58 | 2021-2024 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex), Ovitex 2s |
| Kci USA, INC. | $207.19 | 2019 | |
| Allergan, INC. | $167.37 | 2019 | |
| Braintree Laboratories, INC. | $56.40 | 2020-2023 | Sutab |
| Ethicon US, LLC | $44.16 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.80 | 2021 | |
| Osiris Therapeutics INC. | $18.79 | 2019 | |
| Merck Sharp & Dohme LLC | $17.87 | 2019 | |
| Solventum Corporation | $17.18 | 2024 | Prevena |
| Focal Therapeutics, INC. | $14.45 | 2020 | |
| Acell, INC. | $13.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mauri Lunderman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.